News >

Immunotherapy Revolutionizes Squamous NSCLC, But Biomarker Enhancement Needed

Kristi Rosa
Published: Monday, Jun 17, 2019

Chad Pecot, MD

Chad Pecot, MD
The introduction of immunotherapy to the treatment landscape for stage IV squamous non–small cell lung cancer (NSCLC) has been revolutionary, with thousands of ongoing international trials exploring new combinations, said Chad Pecot, MD. However, better models for evaluating these regimens are desperately needed, as are effective biomarkers for immune response.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication